In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.
Efficacy with lenvatinib (Lenvima) treatment in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation was shown along with a manageable toxicity profile, according to a recent retrospective study.
Outcomes from the single-center study, which was presented at 2022 ASCO Gastrointestinal Cancers Symposium, were comparable to those from the REFLECT trial (NCT01761266), in which researchers excluded patients who underwent liver transplantation.
“Despite of immunotherapeutic advances (atezolizumab [Tecentriq] plus bevacizumab, pembrolizumab [Keyruda] and nivolumab [Opdivo]) in the management of advanced HCC, patients with prior [liver transplantation] are not benefitted because of the risk of allograft rejection, and they are also excluded in most prospective clinical trials for novel agents,” Kyunghye Bang, MD, of the Department of Oncology at Asan Medical Center at the University of Uslan College of Medicine in Seoul, Korea, said during the presentation.
In this study, researchers assessed the impact of lenvatinib in 22 patients with recurrent HCC after liver transplantation who were treated in a medical center in South Korea between November 2019 and March 2021. Patients who weighed 60 kg or more received 12 mg of lenvatinib per day, whereas those who weighed less than 60 mg received 8 mg of the drug per day. Response to lenvatinib and adverse events associated with the treatment were graded by RECIST v1.1 and NCI CTCAE v5.0.
Patients in the study had a median age of 58 years (range, 20-69) and 95.5% (n = 21) were men. The most common HCC etiology was hepatitis B (n = 18; 81.8%). Recurrence after liver transplantation occurred at a median of 6.6 months (95% CI, 4.2-9.1 months). Before treatment with systemic therapy, the most commonly used therapy for recurrent HCC after a liver transplant was transarterial embolization (n = 12; 54.5%).
Most patients at the time of lenvatinib initiation were Child-Pugh A (n = 21; 95.5%), with 15 patients (68.2%) classified as ALBI grade 1 and 7 patients (31.8%) classified as ALBI grade 2. All patients in this study were at BCLC stage C. In addition, lenvatinib was administered as either a first-line (n = 19) or second-line therapy (n = 3).
Lenvatinib demonstrated an objective response rate of 13.6%. The median progression-free survival (PFS) was 6.6 months (95% CI, 3.6-9.5 months) during a median follow-up of 5.2 months (range, 1.7-14.5 months). Also during follow-up, overall survival (OS) was 14.5 months (95% CI, not assessable). The 6-month OS rate was 88.8%, and the 6-month PFS rate was 59.8%.
ALBI grade may be a predictor of OS, as patients with ALBI grade 2 had significantly poorer OS (11.1 months; 95% CI, not accessible) compared with those with ALBI grade 1 (14.5 months; 95% CI, not accessible; P = .011). Adverse events that occurred with lenvatinib treatment included thrombocytopenia (n = 7; 31.8%), hypertension (n = 8; 36.4%) and fatigue (n = 6; 27.3%).
Reference:
Bang K, Yoo C, Ryu M-H, et al. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation: A retrospective analysis. Presented at: 2022 ASCO Gastrointestinal Cancers Symposium; January 20-22, 2022; Virtual. Abstract #410
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More